2.1. Analysis.
Comparison 2: Exenatide vs no treatment (14 months (60.8 weeks) post baseline), Outcome 1: PD motor impairment ‐ MDS‐UPDRS Part III (off medication)
Comparison 2: Exenatide vs no treatment (14 months (60.8 weeks) post baseline), Outcome 1: PD motor impairment ‐ MDS‐UPDRS Part III (off medication)